MCID: HYP014
MIFTS: 52

Hyperuricemia

Categories: Blood diseases, Metabolic diseases

Aliases & Classifications for Hyperuricemia

MalaCards integrated aliases for Hyperuricemia:

Name: Hyperuricemia 12 75 55 44 15 17 72
Blood Urate Raized 12
Uricacidemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1920
MeSH 44 D033461
NCIt 50 C3961
SNOMED-CT 68 35885006
ICD10 33 E79.0
UMLS 72 C0740394

Summaries for Hyperuricemia

Disease Ontology : 12 An acquired metabolic disease that has material basis in an abnormally high level of uric acid in the blood.

MalaCards based summary : Hyperuricemia, also known as blood urate raized, is related to hyperuricemic nephropathy, familial juvenile, 1 and glycogen storage disease ia, and has symptoms including seizures, muscle weakness and fever. An important gene associated with Hyperuricemia is UMOD (Uromodulin), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics. The drugs Selenium and Colchicine have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and liver, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 75 Hyperuricemia is an abnormally high level of uric acid in the blood. In the pH conditions of body fluid,... more...

Related Diseases for Hyperuricemia

Diseases related to Hyperuricemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 382)
# Related Disease Score Top Affiliating Genes
1 hyperuricemic nephropathy, familial juvenile, 1 33.1 UMOD SLC22A12 HPRT1
2 glycogen storage disease ia 32.7 INS G6PC
3 gout 30.7 XDH UMOD SLC2A9 SLC22A12 SLC17A3 SLC17A1
4 nephrolithiasis, uric acid 30.4 XDH HPRT1
5 hypouricemia, renal, 1 30.4 SLC2A9 SLC22A12 HPRT1
6 arteries, anomalies of 29.8 REN INS APOB
7 fatty liver disease, nonalcoholic 1 29.7 INS GPT
8 cerebrovascular disease 29.6 REN INS APOB
9 hypertension, essential 29.5 REN INS APOB ADRB3
10 glucose intolerance 29.5 INS APOB ADRB3
11 vascular disease 29.5 XDH REN INS APOB
12 inherited metabolic disorder 29.4 INS HPRT1 APOB
13 diabetes mellitus, noninsulin-dependent 28.1 INS GPT G6PC APOB ADRB3
14 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome 12.7
15 glomerulocystic kidney disease with hyperuricemia and isosthenuria 12.6
16 deafness hyperuricemia neurologic ataxia 12.2
17 lesch-nyhan syndrome 12.2
18 hyperuricemia, infantile, with abnormal behavior and normal hypoxanthine guanine phosphoribosyltransferase 12.2
19 hyperuricemic nephropathy, familial juvenile, 2 12.0
20 kelley-seegmiller syndrome 12.0
21 glycogen storage disease vii 11.6
22 phosphoribosylpyrophosphate synthetase superactivity 11.6
23 urate oxidase, pseudogene 11.5
24 autosomal dominant tubulointerstitial kidney disease, ren-related 11.5
25 uric acid concentration, serum, quantitative trait locus 1 11.4
26 medullary cystic kidney disease 1 11.4
27 fructose intolerance, hereditary 11.4
28 glycogen storage disease ib 11.3
29 glycogen storage disease ic 11.3
30 autosomal dominant tubulointerstitial kidney disease 11.3
31 osteodysplasia, familial, anderson type 11.1
32 hyperuricemic nephropathy, familial juvenile, 4 11.1
33 familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis 11.1
34 kidney disease 10.8
35 chronic kidney disease 10.7
36 lipid metabolism disorder 10.6
37 hypertriglyceridemia, familial 10.5
38 acute kidney failure 10.5
39 heart disease 10.5
40 fatty liver disease 10.5
41 hypercholesterolemia, familial, 1 10.4
42 coronary heart disease 1 10.4
43 purine-pyrimidine metabolic disorder 10.4 XDH HPRT1
44 non-alcoholic fatty liver disease 10.4
45 nephrolithiasis, calcium oxalate 10.4
46 liver disease 10.4
47 congestive heart failure 10.4
48 glycogen storage disease 10.3
49 adenine phosphoribosyltransferase deficiency 10.3 XDH HPRT1
50 body mass index quantitative trait locus 1 10.3

Graphical network of the top 20 diseases related to Hyperuricemia:



Diseases related to Hyperuricemia

Symptoms & Phenotypes for Hyperuricemia

UMLS symptoms related to Hyperuricemia:


seizures, muscle weakness, fever, polydipsia, dyspnea, edema, cachexia, vertigo, headache, syncope, cyanosis, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes

MGI Mouse Phenotypes related to Hyperuricemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 ABCG2 ADRB3 G6PC HPRT1 INS PFKM
2 homeostasis/metabolism MP:0005376 10.03 ABCG2 ADRB3 APOB G6PC HPRT1 INS
3 growth/size/body region MP:0005378 10.02 ADRB3 APOB G6PC HPRT1 INS REN
4 adipose tissue MP:0005375 9.88 ABCG2 ADRB3 INS SLC2A9 UMOD XDH
5 immune system MP:0005387 9.81 ABCG2 APOB HPRT1 INS PFKM REN
6 liver/biliary system MP:0005370 9.43 ABCG2 APOB G6PC HPRT1 INS SLC2A9
7 renal/urinary system MP:0005367 9.28 ABCG2 G6PC HPRT1 INS REN SLC22A12

Drugs & Therapeutics for Hyperuricemia

Drugs for Hyperuricemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 195)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
2
Colchicine Approved Phase 4 64-86-8 6167 2833
3
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
4
Norethindrone Approved Phase 4 68-22-4 6230
5
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
6
Polyestradiol phosphate Approved Phase 4 28014-46-2
7
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
8
Lithium carbonate Approved Phase 4 554-13-2
9
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
10
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
11
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
12
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
13
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
14
Canagliflozin Approved Phase 4 842133-18-0
15
Allopurinol Approved Phase 4 315-30-0 2094
16
Febuxostat Approved Phase 4 144060-53-7 134018
17
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
18
Rosemary Experimental Phase 4
19
Uric acid Investigational Phase 4 69-93-2 1175
20 Proanthocyanidin Phase 4
21
Procyanidin Phase 4 4852-22-6 147299
22 Antiparasitic Agents Phase 4
23 Antiprotozoal Agents Phase 4
24 Calciferol Phase 4
25 Tubulin Modulators Phase 4
26 Antimitotic Agents Phase 4
27 insulin Phase 4
28 Insulin, Globin Zinc Phase 4
29 Sodium Chloride Symporter Inhibitors Phase 4
30 Natriuretic Agents Phase 4
31 diuretics Phase 4
32 Diacetylrhein Phase 4
33 Contraceptives, Oral Phase 4
34 Estrogens Phase 4
35 Progestins Phase 4
36 HIV Protease Inhibitors Phase 4
37 Contraceptive Agents Phase 4
38
protease inhibitors Phase 4
39 Norethindrone Acetate Phase 4
40 Estradiol 17 beta-cypionate Phase 4
41 Estradiol 3-benzoate Phase 4
42 Gastrointestinal Agents Phase 4
43 Antipsychotic Agents Phase 4
44 Angiotensinogen Phase 4
45 Giapreza Phase 4
46 Antacids Phase 4
47 Proton Pump Inhibitors Phase 4
48 Anti-Ulcer Agents Phase 4
49 Renal Agents Phase 4
50 Hypoglycemic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 169)
# Name Status NCT ID Phase Drugs
1 Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines Unknown status NCT02797028 Phase 4 Allopurinol
2 Effect of Multi-vitamins With Minerals on Uric Acid Metabolism in Subjects With Hyperuricemia: A Randomized, Double-blinded, Placebo-controlled Trail Unknown status NCT03218709 Phase 4
3 Program of Rasburicase in the Treatment of Hyperuricemia in Children and Adolescent Patients With or at Risk of Tumor Lysis Syndrome. Completed NCT00302653 Phase 4 Rasburicase
4 Phase IV, Compassionate Use Program of Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Completed NCT00563771 Phase 4 Rasburicase
5 Prednisone Versus Allopurinol for Symptomatic Heart Failure Patients With Hyperuricemia Completed NCT00919243 Phase 4 prednisone;allopurinol
6 Hyperuricemia and the Effects of the Uricosuric Agents Benzbromarone in Patients With Chronic Heart Failure Completed NCT00422318 Phase 4 Benzbromarone (drug)
7 A Multicenter Open Label Study of the Efficacy and Safety of Rasburicase in the Treatment of Prophylysis for Tumor Lysis Syndrome Completed NCT00651911 Phase 4 urate oxidase
8 Febuxostat (Zurig) Efficacy & Safety Trial in Comparison With Allopurinol in Hyperuricemic Subjects With or Without Gout Completed NCT02600780 Phase 4 Febuxostat;Allopurinol
9 Effects of Pharmacological Reversal of Hyperuricemia on Features of the Metabolic Syndrome Completed NCT01654276 Phase 4 Febuxostat
10 Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO) Completed NCT01391325 Phase 4 Allopurinol
11 A Double-blind, Placebo-controlled, Cross-over Study of the Effects of Allopurinol on Oxidative Metabolism, Peripheral Blood Flow and Immune Function in Patients With Advanced Chronic Heart Failure (CHF). Completed NCT00997542 Phase 4 Allopurinol;Placebo
12 Evaluation of Single Agent Rasburicase in Treatment/Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Adult and Pediatric Patients With Lymphoma/Leukemia/Solid Tumor Malignancies at Their First Relapse or Refractory Disease Completed NCT00230217 Phase 4 Rasburicase (SR29142)
13 Diacerein Combined With Febuxostat Relieves Symptoms of Gout by Suppressing IL-1βinflammation Completed NCT02060552 Phase 4 Diacerein;Colchicine;Febuxostat
14 Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women. Completed NCT03921736 Phase 4 Perindopril;Hydrochlorothiazide;Estracomb TTS
15 A Double-Blind, Placebo Controlled Augmentation Study With Allopurinol for Treatment Resistant Mania Completed NCT00643123 Phase 4 Allopurinol
16 Weight Loss Improves Renal Hemodynamics in Patients With Metabolic Syndrome Completed NCT01356394 Phase 4
17 Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS) Completed NCT01328769 Phase 4 Febuxostat;Placebo
18 The Effect of Intensive Urate Lowering Therapy (ULT) With Febuxostat in Comparison With Allopurinol on Cardiovascular Risk in Patients With Gout Using Surrogate Markers: a Randomized, Controlled Trial Completed NCT02500641 Phase 4 Febuxostat 80/120mg/day;Allopurinol 100 up to 600mg/day;Colchicine;Naproxen;Omeprazole
19 Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients: A Prospective, Multicenter, Double-Blinded, Randomized Controlled Trial Recruiting NCT03200210 Phase 4 Febuxostat;Placebo
20 Study on the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention Recruiting NCT03425708 Phase 4 20mg Febuxostat;40mg Febuxostat
21 The Cardiovascular Effects of Febuxostat and Benzbromarone on Left Ventricle Diastolic Dysfunction in Individuals With Metabolic Syndrome and Hyperuricemia - an Open-label Non-blinded Randomized-controlled Clinical Trial Active, not recruiting NCT03534037 Phase 4 Febuxostat 40 mg;Benzbromarone 50mg
22 The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Active, not recruiting NCT02956278 Phase 4 Allopurinol
23 Pharmacogenetics of Sodium-dependent Glucose Transporter-2 (SGLT2) Inhibitors Active, not recruiting NCT02462421 Phase 4 Canagliflozin
24 The Impact of Urate-lowering Therapy on Kidney Function in Patients With/Without Gout Enrolling by invitation NCT03336203 Phase 4 Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet
25 A Single-center, Prospective, Randomized, Double-blind, Controlled Trial for the Effect of Allopurinol Sustained-release Capsules on the Stability of Coronary Plaques in Patients With Acute Coronary Syndrome Not yet recruiting NCT03745729 Phase 4 allopurinol sustained-release capsules;placebo capsules
26 the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia Terminated NCT02279342 Phase 4 Febuxostat
27 Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn Withdrawn NCT03007381 Phase 4 Ketorolac Tromethamine;Normal Saline
28 Long-term Prednisone Use in Patients With Advanced Heart Failure (ACCF/AHA Stage D) and Hyperuricemia Unknown status NCT02282683 Phase 2, Phase 3 prednisone
29 The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients Unknown status NCT02563405 Phase 2, Phase 3 Doxazosin;Nifedipine
30 Official Title: Safety and Efficacy Evaluation Study of FYU-981 Long-term Administration for Hyperuricemia With or Without Gout (Phase III Study) Completed NCT03006445 Phase 3 FYU-981
31 Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study) Completed NCT03100318 Phase 3 FYU-981;Benzbromarone
32 Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study) Completed NCT03372200 Phase 3 FYU-981;Febuxostat
33 Prednisone in Uric Acid Lowering in Symptomatic Heart Failure PATients With Hyperuricemia (PUSH-PATH Study 2) Completed NCT02129764 Phase 2, Phase 3 Prednisone;Allopurinol
34 Evaluation of Single Agent Rasburicase for 5 Days Versus Sequential Treatment With Rasburicase From Day 1 Through 3 Followed by Oral Allopurinol From Day 3 Through 5 (Overlap on Day 3) Versus Single Agent Oral Allopurinol for 5 Days in the Management of Plasma Uric Acid in Adult Patients With Leukemia, Lymphoma, and Solid Tumor Malignancies at Risk for Hyperuricemia and Tumor Lysis Syndrome Completed NCT00230178 Phase 3 Rasburicase (SR29142);Allopurinol
35 Randomised Phase III Trial of Effectivity and Safety of Rasburicase Compared With Allopurinol for Treatment of Hyperuricemia in Patients With Acute Lymphoblastic Leukemia or High-Grade NHL With High Risk of Tumorlysis Syndrome (> 15 Yrs) Completed NCT00199043 Phase 3 Allopurinol;Rasburicase
36 Efficacy and Safety of TULY in Prevention and Treatment of Malignancy-associated Hyperuricemia Completed NCT00921375 Phase 3 TULY
37 A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout. Completed NCT00430248 Phase 3 Febuxostat;Febuxostat;Allopurinol
38 A Phase 3, Open-Label, Randomized, Allopurinol-Controlled Study to Assess the Long-Term Safety of Oral Febuxostat in Subjects With Gout Completed NCT00175019 Phase 3 Febuxostat;Febuxostat;Allopurinol
39 UAB Center of Research Translation (CORT) Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure Completed NCT02038179 Phase 2, Phase 3 Allopurinol;Placebo
40 Uric Acid and Hypertension in African Americans Completed NCT00241839 Phase 3 Allopurinol;Placebo;Chlorthalidone;Potassium chloride
41 A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities Completed NCT01101035 Phase 3 Febuxostat;Allopurinol
42 Randomized, Multicenter, Double-blind, Placebo-controlled Efficacy and Safety Study of 8 mg PEG-uricase in Two Dose Regimens in Hyperuricemic Subjects With Symptomatic Gout Completed NCT00325195 Phase 3
43 Low Osmolar Diet and Adjusted Water Intake for Vasopressin Suppression in ADPKD Completed NCT02225860 Phase 2, Phase 3
44 BOsentan for Mild Pulmonary Vascular Disease in Asd Patients (the BOMPA Trial): a Double-blind, Randomized Controlled, Pilot Trial Completed NCT01218607 Phase 3 Bosentan;Placebo
45 Colchicine or Prednisone for the Treatment of Acute Calcium Pyrophosphate Deposition (CPPD) Arthritis: Open-label, Randomized, Multicenter, Equivalence Trial of Efficacy and Safety Recruiting NCT03128905 Phase 3 Colchicine opocalcium 1mg;Prednisone : Cortancyl 20mg
46 Effects of Allopurinol on Inflammatory Markers and Morphostructural Changes Evidenced by Musculoskeletal Ultrasound in Individuals With Asymptomatic Hyperuricemia. A Proof of Concept Not yet recruiting NCT04012294 Phase 3 Allopurinol Pill
47 A Multi-center, Randomized, Open-label, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Patients With Hematological Malignancies Terminated NCT00607152 Phase 3 Rasburicase;Allopurinol
48 Trial of Kuvan™ (Sapropterin) Treatment in Patients With Lesch Nyhan Disease Withdrawn NCT00935753 Phase 2, Phase 3 sapropterin
49 Open-Label, Inpatient Study of Levotofisopam 50 mg TID Administered for 7 Days to Men and Postmenopausal Women With Hyperuricemia and Gout Unknown status NCT01519687 Phase 2 levotofisopam
50 A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product. Unknown status NCT00208000 Phase 2 Marine active

Search NIH Clinical Center for Hyperuricemia

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Allopurinol
Lesinurad
Mannitol hexanitrate
Probenecid
Rasburicase
Rasburicase
Sulfinpyrazone

Cochrane evidence based reviews: hyperuricemia

Genetic Tests for Hyperuricemia

Anatomical Context for Hyperuricemia

MalaCards organs/tissues related to Hyperuricemia:

41
Kidney, Heart, Liver, Endothelial, Bone, Testes, Breast

Publications for Hyperuricemia

Articles related to Hyperuricemia:

(show top 50) (show all 6355)
# Title Authors PMID Year
1
Childhood course of renal insufficiency in a family with a uromodulin gene mutation. 9 38
20151160 2010
2
Uric acid transport and disease. 9 38
20516647 2010
3
Uric acid as a factor in the metabolic syndrome. 9 38
20424936 2010
4
[Association between the risk factors of cardiovascular diseases and insulin resistance]. 9 38
20513276 2010
5
Glomerulocystic kidney: one hundred-year perspective. 9 38
20367310 2010
6
Trp64Arg polymorphism of the ADRB3 gene predicts hyperuricemia risk in a population from southern Spain. 9 38
20008926 2010
7
Allopurinol, xanthine oxidase, and cardiac ischemia. 9 38
19794315 2009
8
Uric acid concentrations are associated with insulin resistance and birthweight in normotensive pregnant women. 9 38
19729142 2009
9
Serum uric acid is associated with metabolic risk factors for cardiovascular disease in the Uygur population. 9 38
20029511 2009
10
Myelination disturbance in a patient with hyperuricemia and hyperserotoninemia combined with 18q deletion syndrome. 9 38
20025132 2009
11
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. 9 38
20109996 2009
12
Utility of waist-to-height ratio in detecting central obesity and related adverse cardiovascular risk profile among normal weight younger adults (from the Bogalusa Heart Study). 9 38
19699351 2009
13
Severe gouty arthritis and mild neurologic symptoms due to F199C, a newly identified variant of the hypoxanthine guanine phosphoribosyltransferase. 9 38
19565499 2009
14
Febuxostat (Uloric) for chronic treatment of gout. 9 38
19448587 2009
15
Increased xanthine oxidase in the skin of preeclamptic women. 9 38
19196876 2009
16
Hypertension in the metabolic syndrome: summary of the new position statement of the European Society of Hypertension. 9 38
19413186 2009
17
Relationship of serum gamma-glutamyltransferase to atherogenic dyslipidemia and glycemic control in type 2 diabetes. 9 38
19057528 2009
18
Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. 9 38
18060751 2008
19
The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. 9 38
18635756 2008
20
[Inhibitors of xanthine oxidoreductase]. 9 38
18409526 2008
21
[Relationship between hyperuricemia and metabolic syndrome]. 9 38
18409529 2008
22
[Uricosuric agent]. 9 38
18409525 2008
23
[Primary hyperuricemia due to decreased renal uric acid excretion]. 9 38
18409514 2008
24
[New antihyperuricemic medicine: febuxostat, Puricase, etc]. 9 38
18409528 2008
25
[Uromodulin mutation and hyperuricemia]. 9 38
18409531 2008
26
In addition to insulin resistance and obesity, hyperuricemia is strongly associated with metabolic syndrome using different definitions in Chinese populations: a population-based study (Taichung Community Health Study). 9 38
18292110 2008
27
Control of renal uric acid excretion and gout. 9 38
18349750 2008
28
Substrate orientation in xanthine oxidase: crystal structure of enzyme in reaction with 2-hydroxy-6-methylpurine. 9 38
18063585 2008
29
Uric acid: a surrogate of insulin resistance in older women. 9 38
18082342 2008
30
Diabetes and nephrolithiasis. 9 38
18255008 2007
31
Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. 9 38
18067674 2007
32
[Relation of serum uric acid levels with basic metabolic parameters in patients with metabolic syndrome during insulin-sensitizing therapy]. 9 38
18071212 2007
33
Thiazide diuretics exacerbate fructose-induced metabolic syndrome. 9 38
17855639 2007
34
The metabolic syndrome in hypertension: diagnostic and therapeutic implications. 9 38
17686382 2007
35
The association between hyperuricemia and the Trp64Arg polymorphism of the beta-3 adrenergic receptor. 9 38
17225053 2007
36
Serum uric acid and leptin levels in metabolic syndrome: a quandary over the role of uric acid. 9 38
17512306 2007
37
Prevalence of the metabolic syndrome in individuals with hyperuricemia. 9 38
17466656 2007
38
Elevated uric acid levels predict allograft vasculopathy in cardiac transplant recipients. 9 38
17449420 2007
39
Association between silent ST segment depression in exercise electrocardiography and insulin resistance in obese subjects. 9 38
17552288 2007
40
Genetics and experimental models of crystal-induced arthritis. Lessons learned from mice and men: is it crystal clear? 9 38
17278928 2007
41
Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. 9 38
19075968 2007
42
Hypoxanthine-guanine phosphoribosyltransferase deficiency: biochemical and molecular findings in six Argentine patients. 9 38
17454734 2007
43
Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. 9 38
17132810 2006
44
Association between intronic SNP in urate-anion exchanger gene, SLC22A12, and serum uric acid levels in Japanese. 9 38
16920156 2006
45
New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer). 9 38
17119268 2006
46
[An analysis of islet beta-cell function in hyperuricemia]. 9 38
16831320 2006
47
Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. 9 38
16708061 2006
48
New developments in clinically relevant mechanisms and treatment of hyperuricemia. 9 38
16901081 2006
49
Metabolic syndrome in subjects with essential hypertension: relationships with subclinical cardiovascular and renal damage. 9 38
16778751 2006
50
Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. 9 38
16507884 2006

Variations for Hyperuricemia

Expression for Hyperuricemia

Search GEO for disease gene expression data for Hyperuricemia.

Pathways for Hyperuricemia

GO Terms for Hyperuricemia

Cellular components related to Hyperuricemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.1 UMOD SLC2A9 SLC22A12 SLC17A3 SLC17A1 PFKM
2 endosome lumen GO:0031904 8.96 INS APOB

Biological processes related to Hyperuricemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.8 SLC2A9 SLC22A12 SLC17A3 SLC17A1 ABCG2
2 glucose homeostasis GO:0042593 9.61 PFKM INS G6PC
3 glycogen catabolic process GO:0005980 9.37 PFKM G6PC
4 phosphate ion transport GO:0006817 9.32 SLC17A3 SLC17A1
5 sialic acid transport GO:0015739 9.26 SLC17A3 SLC17A1
6 urate transport GO:0015747 9.26 SLC2A9 SLC22A12 SLC17A3 SLC17A1
7 cholesterol efflux GO:0033344 9.16 APOB
8 glucose-6-phosphate transport GO:0015760 9.16 SLC17A3 G6PC
9 urate metabolic process GO:0046415 9.1 SLC2A9 SLC22A12 SLC17A3 SLC17A1 G6PC ABCG2

Molecular functions related to Hyperuricemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.72 XDH PFKM HPRT1 ADRB3 ABCG2
2 insulin-like growth factor receptor binding GO:0005159 9.16 REN INS
3 cholesterol transporter activity GO:0017127 8.96 APOB
4 sialic acid transmembrane transporter activity GO:0015136 8.96 SLC17A3 SLC17A1
5 urate transmembrane transporter activity GO:0015143 8.8 SLC2A9 SLC22A12 SLC17A3

Sources for Hyperuricemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....